Adverse Reaction Risk - XML Representation - Sparked Logical Models v0.0.1

Sparked Logical Models, published by CSIRO. This guide is not an authorized publication; it is the continuous build for version 0.0.1 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/aehrc/logical-model-web/ and changes regularly. See the Directory of published versions
Logical Model: AdverseReactionRisk - XML Profile

Draft as of 2023-09-11
XML representation of the AdverseReactionRisk logical model.
Raw xml | Download

<StructureDefinition xmlns="http://hl7.org/fhir">
  <id value="AdverseReactionRisk"/>
  <text>
    <status value="extensions"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: StructureDefinition AdverseReactionRisk</b></p><table border="0" cellpadding="0" cellspacing="0" style="border: 0px #F0F0F0 solid; font-size: 11px; font-family: verdana; vertical-align: top;"><tr style="border: 1px #F0F0F0 solid; font-size: 11px; font-family: verdana; vertical-align: top"><th style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; padding-top: 3px; padding-bottom: 3px" class="hierarchy"><a href="https://build.fhir.org/ig/FHIR/ig-guidance/readingIgs.html#table-views" title="The logical name of the element">Name</a></th><th style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; padding-top: 3px; padding-bottom: 3px" class="hierarchy"><a href="https://build.fhir.org/ig/FHIR/ig-guidance/readingIgs.html#table-views" title="Information about the use of the element">Flags</a></th><th style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; padding-top: 3px; padding-bottom: 3px" class="hierarchy"><a href="https://build.fhir.org/ig/FHIR/ig-guidance/readingIgs.html#table-views" title="Minimum and Maximum # of times the element can appear in the instance">Card.</a></th><th style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; padding-top: 3px; padding-bottom: 3px; width: 100px" class="hierarchy"><a href="https://build.fhir.org/ig/FHIR/ig-guidance/readingIgs.html#table-views" title="Reference to the type of the element">Type</a></th><th style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; padding-top: 3px; padding-bottom: 3px" class="hierarchy"><a href="https://build.fhir.org/ig/FHIR/ig-guidance/readingIgs.html#table-views" title="Additional information about the element">Description &amp; Constraints</a><span style="float: right"><a href="https://build.fhir.org/ig/FHIR/ig-guidance/readingIgs.html#table-views" title="Legend for this format"><img src="data:image/png;base64,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" alt="doco" style="background-color: inherit"/></a></span></th></tr><tr style="border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: white"><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck1.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="icon_element.gif" alt="." style="background-color: white; background-color: inherit" title="Element" class="hierarchy"/> <a href="StructureDefinition-AdverseReactionRisk-definitions.html#AdverseReactionRisk" title="Clinical assessment of the propensity for an individual to experience a harmful or undesirable physiological response if exposed, or re-exposed, to a substance.">AdverseReactionRisk</a><a name="AdverseReactionRisk"> </a></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"><span style="padding-left: 3px; padding-right: 3px; color: white; background-color: #D50000" title="This element must be supported">S</span></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy">0..*</td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"><a href="http://build.fhir.org/types.html#Base">Base</a></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy">Adverse Reaction Risk<br/></td></tr>
<tr style="border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: #F7F7F7"><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck11.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="icon_datatype.gif" alt="." style="background-color: #F7F7F7; background-color: inherit" title="Data Type" class="hierarchy"/> <a href="StructureDefinition-AdverseReactionRisk-definitions.html#AdverseReactionRisk.Protocol" title="@ internal @">Protocol</a><a name="AdverseReactionRisk.Protocol"> </a></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"><span style="padding-left: 3px; padding-right: 3px; color: white; background-color: #D50000" title="This element must be supported">S</span></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy">0..1</td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"><a href="http://hl7.org/fhir/R4/datatypes.html#BackboneElement">BackboneElement</a></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy">Protocol</td></tr>
<tr style="border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: white"><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck110.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_vline.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="icon_primitive.png" alt="." style="background-color: white; background-color: inherit" title="Primitive Data Type" class="hierarchy"/> <a href="StructureDefinition-AdverseReactionRisk-definitions.html#AdverseReactionRisk.Protocol.Lastupdated" title="Date when the propensity or the reaction event was updated.">Lastupdated</a><a name="AdverseReactionRisk.Protocol.Lastupdated"> </a></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"><span style="padding-left: 3px; padding-right: 3px; color: white; background-color: #D50000" title="This element must be supported">S</span></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy">0..1</td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"><a href="http://hl7.org/fhir/R4/datatypes.html#dateTime">dateTime</a></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy">Last updated</td></tr>
<tr style="border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: #F7F7F7"><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck100.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_vline.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_vjoin_end.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="icon_reference.png" alt="." style="background-color: #F7F7F7; background-color: inherit" title="Reference to another Resource" class="hierarchy"/> <a href="StructureDefinition-AdverseReactionRisk-definitions.html#AdverseReactionRisk.Protocol.Extension" title="Additional information required to capture local content or to align with other reference models/formalisms.">Extension</a><a name="AdverseReactionRisk.Protocol.Extension"> </a></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"><span style="padding-left: 3px; padding-right: 3px; color: white; background-color: #D50000" title="This element must be supported">S</span></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy">0..1</td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"><a href="http://hl7.org/fhir/R4/references.html">Reference</a>()</td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy">Extension</td></tr>
<tr style="border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: white"><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck01.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_vjoin_end.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="icon_datatype.gif" alt="." style="background-color: white; background-color: inherit" title="Data Type" class="hierarchy"/> <a href="StructureDefinition-AdverseReactionRisk-definitions.html#AdverseReactionRisk.Data" title="@ internal @">Data</a><a name="AdverseReactionRisk.Data"> </a></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"><span style="padding-left: 3px; padding-right: 3px; color: white; background-color: #D50000" title="This element must be supported">S</span></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy">0..1</td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"><a href="http://hl7.org/fhir/R4/datatypes.html#BackboneElement">BackboneElement</a></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy">Data</td></tr>
<tr style="border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: #F7F7F7"><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck010.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="icon_datatype.gif" alt="." style="background-color: #F7F7F7; background-color: inherit" title="Data Type" class="hierarchy"/> <a href="StructureDefinition-AdverseReactionRisk-definitions.html#AdverseReactionRisk.Data.Substance" title="Identification of a substance, or substance class, that is considered to put the individual at risk of an adverse reaction event.">Substance</a><a name="AdverseReactionRisk.Data.Substance"> </a></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"><span style="padding-left: 3px; padding-right: 3px; color: white; background-color: #D50000" title="This element must be supported">S</span></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy">1..1</td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"><a href="http://hl7.org/fhir/R4/datatypes.html#CodeableConcept">CodeableConcept</a></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy">Substance</td></tr>
<tr style="border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: white"><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck010.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="icon_datatype.gif" alt="." style="background-color: white; background-color: inherit" title="Data Type" class="hierarchy"/> <a href="StructureDefinition-AdverseReactionRisk-definitions.html#AdverseReactionRisk.Data.Activeinactivestatus" title="Status about whether the adverse reaction risk statement is active or inactive.">Activeinactivestatus</a><a name="AdverseReactionRisk.Data.Activeinactivestatus"> </a></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"><span style="padding-left: 3px; padding-right: 3px; color: white; background-color: #D50000" title="This element must be supported">S</span></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy">0..1</td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"><a href="http://hl7.org/fhir/R4/datatypes.html#Coding">Coding</a></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy">Activeinactivestatus</td></tr>
<tr style="border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: #F7F7F7"><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck010.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="icon_datatype.gif" alt="." style="background-color: #F7F7F7; background-color: inherit" title="Data Type" class="hierarchy"/> <a href="StructureDefinition-AdverseReactionRisk-definitions.html#AdverseReactionRisk.Data.Verificationstatus" title="Assertion about the certainty of the propensity, or potential future risk, of the identified 'Substance' to cause a reaction.">Verificationstatus</a><a name="AdverseReactionRisk.Data.Verificationstatus"> </a></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"><span style="padding-left: 3px; padding-right: 3px; color: white; background-color: #D50000" title="This element must be supported">S</span></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy">0..1</td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"><a href="http://hl7.org/fhir/R4/datatypes.html#Coding">Coding</a></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy">Verification status</td></tr>
<tr style="border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: white"><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck010.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="icon_datatype.gif" alt="." style="background-color: white; background-color: inherit" title="Data Type" class="hierarchy"/> <a href="StructureDefinition-AdverseReactionRisk-definitions.html#AdverseReactionRisk.Data.Criticality" title="An indication of the potential for critical system organ damage or life threatening consequence.">Criticality</a><a name="AdverseReactionRisk.Data.Criticality"> </a></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"><span style="padding-left: 3px; padding-right: 3px; color: white; background-color: #D50000" title="This element must be supported">S</span></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy">0..1</td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"><a href="http://hl7.org/fhir/R4/datatypes.html#CodeableConcept">CodeableConcept</a></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy">Criticality</td></tr>
<tr style="border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: #F7F7F7"><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck010.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="icon_datatype.gif" alt="." style="background-color: #F7F7F7; background-color: inherit" title="Data Type" class="hierarchy"/> <a href="StructureDefinition-AdverseReactionRisk-definitions.html#AdverseReactionRisk.Data.Category" title="Category of the identified 'Substance'.">Category</a><a name="AdverseReactionRisk.Data.Category"> </a></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"><span style="padding-left: 3px; padding-right: 3px; color: white; background-color: #D50000" title="This element must be supported">S</span></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy">0..1</td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"><a href="http://hl7.org/fhir/R4/datatypes.html#CodeableConcept">CodeableConcept</a></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy">Category</td></tr>
<tr style="border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: white"><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck011.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="icon_choice.gif" alt="." style="background-color: white; background-color: inherit" title="Choice of Types" class="hierarchy"/> <a href="StructureDefinition-AdverseReactionRisk-definitions.html#AdverseReactionRisk.Data.Onsetoflastreaction" title="The date and/or time of the onset of the last known occurrence of a reaction event.">Onsetoflastreaction</a><a name="AdverseReactionRisk.Data.Onsetoflastreaction"> </a></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"><span style="padding-left: 3px; padding-right: 3px; color: white; background-color: #D50000" title="This element must be supported">S</span></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy">0..1</td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"/><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy">Onset of last reaction</td></tr>
<tr style="border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: #F7F7F7"><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck0110.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_vline.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="icon_primitive.png" alt="." style="background-color: #F7F7F7; background-color: inherit" title="Primitive Data Type" class="hierarchy"/> <span title="Base StructureDefinition for dateTime Type: A date, date-time or partial date (e.g. just year or year + month).  If hours and minutes are specified, a time zone SHALL be populated. The format is a union of the schema types gYear, gYearMonth, date and dateTime. Seconds must be provided due to schema type constraints but may be zero-filled and may be ignored.                 Dates SHALL be valid dates.">Onsetoflastreaction</span></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"/><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"/><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"><a href="http://hl7.org/fhir/R4/datatypes.html#dateTime">dateTime</a></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"/></tr>
<tr style="border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: white"><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck0100.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_vline.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_vjoin_end.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="icon_primitive.png" alt="." style="background-color: white; background-color: inherit" title="Primitive Data Type" class="hierarchy"/> <span title="Base StructureDefinition for string Type: A sequence of Unicode characters">Onsetoflastreaction</span></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"/><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"/><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"><a href="http://hl7.org/fhir/R4/datatypes.html#string">string</a></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"/></tr>
<tr style="border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: #F7F7F7"><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck011.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="icon_choice.gif" alt="." style="background-color: #F7F7F7; background-color: inherit" title="Choice of Types" class="hierarchy"/> <a href="StructureDefinition-AdverseReactionRisk-definitions.html#AdverseReactionRisk.Data.Onsetoffirstreaction" title="The onset of the first known occurrence of a reaction event.">Onsetoffirstreaction</a><a name="AdverseReactionRisk.Data.Onsetoffirstreaction"> </a></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"><span style="padding-left: 3px; padding-right: 3px; color: white; background-color: #D50000" title="This element must be supported">S</span></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy">0..1</td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"/><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy">Onset of first reaction</td></tr>
<tr style="border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: white"><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck0110.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_vline.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="icon_primitive.png" alt="." style="background-color: white; background-color: inherit" title="Primitive Data Type" class="hierarchy"/> <span title="Base StructureDefinition for dateTime Type: A date, date-time or partial date (e.g. just year or year + month).  If hours and minutes are specified, a time zone SHALL be populated. The format is a union of the schema types gYear, gYearMonth, date and dateTime. Seconds must be provided due to schema type constraints but may be zero-filled and may be ignored.                 Dates SHALL be valid dates.">Onsetoffirstreaction</span></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"/><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"/><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"><a href="http://hl7.org/fhir/R4/datatypes.html#dateTime">dateTime</a></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"/></tr>
<tr style="border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: #F7F7F7"><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck0100.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_vline.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_vjoin_end.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="icon_primitive.png" alt="." style="background-color: #F7F7F7; background-color: inherit" title="Primitive Data Type" class="hierarchy"/> <span title="Base StructureDefinition for string Type: A sequence of Unicode characters">Onsetoffirstreaction</span></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"/><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"/><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"><a href="http://hl7.org/fhir/R4/datatypes.html#string">string</a></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"/></tr>
<tr style="border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: white"><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck010.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="icon_datatype.gif" alt="." style="background-color: white; background-color: inherit" title="Data Type" class="hierarchy"/> <a href="StructureDefinition-AdverseReactionRisk-definitions.html#AdverseReactionRisk.Data.Reactionmechanism" title="Identification of the underlying physiological mechanism for the adverse reaction.">Reactionmechanism</a><a name="AdverseReactionRisk.Data.Reactionmechanism"> </a></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"><span style="padding-left: 3px; padding-right: 3px; color: white; background-color: #D50000" title="This element must be supported">S</span></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy">0..1</td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"><a href="http://hl7.org/fhir/R4/datatypes.html#CodeableConcept">CodeableConcept</a></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy">Reaction mechanism</td></tr>
<tr style="border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: #F7F7F7"><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck010.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_vjoin.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="icon_reference.png" alt="." style="background-color: #F7F7F7; background-color: inherit" title="Reference to another Resource" class="hierarchy"/> <a href="StructureDefinition-AdverseReactionRisk-definitions.html#AdverseReactionRisk.Data.Reactioneventsummary" title="Summary details about each adverse reaction event linked to exposure to the identified 'Substance'.">Reactioneventsummary</a><a name="AdverseReactionRisk.Data.Reactioneventsummary"> </a></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"><span style="padding-left: 3px; padding-right: 3px; color: white; background-color: #D50000" title="This element must be supported">S</span></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy">0..*</td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"><a href="http://hl7.org/fhir/R4/references.html">Reference</a>(<a href="StructureDefinition-AdverseReactionEvent.html">Adverse Reaction Event</a>)</td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy">Reaction event summary<br/></td></tr>
<tr style="border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: white"><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck000.png)" class="hierarchy"><img src="tbl_spacer.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_blank.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="tbl_vjoin_end.png" alt="." style="background-color: inherit" class="hierarchy"/><img src="icon_primitive.png" alt="." style="background-color: white; background-color: inherit" title="Primitive Data Type" class="hierarchy"/> <a href="StructureDefinition-AdverseReactionRisk-definitions.html#AdverseReactionRisk.Data.Comment" title="Additional narrative about the propensity for the adverse reaction, not captured in other fields.">Comment</a><a name="AdverseReactionRisk.Data.Comment"> </a></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"><span style="padding-left: 3px; padding-right: 3px; color: white; background-color: #D50000" title="This element must be supported">S</span></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy">0..1</td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy"><a href="http://hl7.org/fhir/R4/datatypes.html#string">string</a></td><td style="vertical-align: top; text-align : var(--ig-left,left); background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px" class="hierarchy">Comment</td></tr>
<tr><td colspan="5" class="hierarchy"><br/><a href="https://build.fhir.org/ig/FHIR/ig-guidance/readingIgs.html#table-views" title="Legend for this format"><img src="data:image/png;base64,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" alt="doco" style="background-color: inherit"/> Documentation for this format</a></td></tr></table></div>
  </text>
  <url
       value="https://aehrc.csiro.au/fhir/logical-models/AdverseReactionRisk"/>
  <identifier>
    <system value="https://aehrc.csiro.au/id/archetype_id"/>
    <value value="openEHR-EHR-EVALUATION.adverse_reaction_risk.v2"/>
  </identifier>
  <version value="0.0.1"/>
  <name value="AdverseReactionRisk"/>
  <title value="Adverse Reaction Risk"/>
  <status value="draft"/>
  <experimental value="false"/>
  <date value="2023-09-11T00:54:09+10:00"/>
  <publisher value="CSIRO"/>
  <contact>
    <name value="CSIRO"/>
    <telecom>
      <system value="url"/>
      <value value="https://aehrc.csiro.au/"/>
    </telecom>
  </contact>
  <contact>
    <name value="AU logical models"/>
    <telecom>
      <system value="url"/>
      <value value="https://aehrc.csiro.au/"/>
    </telecom>
  </contact>
  <description
               value="The Adverse Reaction Risk Logical Model Mindmap is shown below.

&lt;div&gt;&lt;img src='data:image/png;base64,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'/&gt;&lt;/div&gt;

Clinical assessment of the propensity for an individual to experience a harmful or undesirable physiological response if exposed, or re-exposed, to a substance.

**Purpose**

To record the clinical assessment of the propensity for an individual to experience an adverse reaction if exposed, or re-exposed, to a specified substance or class of substances.

**Misuse**

Not to be used for recording physiological reactions to physical agents, such as heat, cold, sunlight, vibration, exercise activity, by infectious agents or food contaminants. Use a specific archetype for EVALUATION.problem/diagnosis or CLUSTER.symptom/sign for this purpose.

Not to be used to record adverse events, including failures of clinical process, interventions or products. For example: abnormal use, incorrect dosage or maladministration of an agent or substance; mislabelling; harm or injury caused by an intervention or procedure; overdose/poisoning etc. Use a specific archetype for the purpose. 

Not to be used to record an adverse reaction where the substance is unknown. Use EVALUATION.problem_diagnosis or CLUSTER.symptom_sign to record as part of the health record until a possible substance is identified.

Not to be used to record reactions to transfusions of blood products. Use a specific archetype for this purpose. 

Not to be used for recording 'alerts'. Use EVALUATION.precaution, EVALUATION.contraindication or related archetypes for this purpose.

Not to be used for recording failed therapy.

Not to be used for the explicit recording of an absence (or negative presence) of a reaction to 'any substances' or to identified substances, for example ‘No known allergies or adverse reactions’ or ‘No known allergies to Penicillin’. Use the EVALUATION.exclusion_global or EVALUATION.exclusion_specific archetypes to express a positive statement of adverse reaction exclusion.

Not to be used for the explicit recording that no information was able to be obtained about the adverse reaction status of a patient. Use the EVALUATION.absence archetype to record that a positive statement that information was not able to be obtained, for example, if a non-cooperative patient refuses to answer questions.

**Considerations**

Use to record a clinical assessment of a propensity for an adverse reaction upon future exposure to a specified substance or class of substances including, but not limited to, incipients and excipients in medicinal preparations, biological products, metal salts, and organic chemical compounds. 

This archetype is intended to provide a single place within the health record to document the propensity for the full range of reactions, from trivial to life-threatening:
- immune-mediated: Types I-IV (including allergic reactions and hypersensitivities); or 
- non-immune-mediated: including pseudo-allergic reactions, side effects, intolerances, and drug toxicities.
In clinical practice distinguishing between immune-mediated and non-immune-mediated reactions can be difficult. Identification of the type of reaction is not a proxy for seriousness or risk of harm to the patient.

Where a propensity is identified, information or evidence about one or more reaction events can be recorded using the CLUSTER.adverse_reaction_event archetype in the 'Reaction event summary' SLOT.

Identification of the severity of the manifestation of the reaction, recorded in the CLUSTER.adverse_reaction_event archetype, can inform the 'Criticality' of the adverse reaction risk. For example, experiencing anaphylaxis on first exposure to a substance would warrant setting a 'Criticality' of 'high', due to the high risk that anaphylaxis is likely to recur on second and subsequent exposures.

This archetype has been designed to allow the recording of information about a specific substance (amoxycillin, oysters, or bee sting venom) or, alternatively, a class of substance (e.g. Penicillins). If a class of substance is recorded, identification of the exact substance can be recorded on a per-reaction basis using the CLUSTER.adverse_reaction_event archetype.

Use to record information about the positive presence of the risk of an adverse reaction:
- to support the direct clinical care of an individual; 
- as part of a managed adverse reaction or allergy/intolerance list; 
- to support the exchange of information about the propensity and events related to adverse reactions; 
- to inform adverse reaction reporting; and 
- to assist with computerised knowledge-based activities such as clinical decision support and alerts.

The risk of an adverse reaction event or manifestation must always propose a causative substance or class of substance. If there is a degree of uncertainty that a specific substance is the cause, the level of uncertainty can be recorded using the ‘Verification status’ data element. If more than one possible substance may have caused a reaction/manifestation, each substance should be recorded using a separate instance of this adverse reaction risk archetype with the ‘Verification status’ set to an initial state of ‘Unconfirmed’ so that adverse reaction checking can be activated in clinical systems. If the substance is later proven not to be causal then the ‘Verification status’ can be modified to ‘Refuted’ - for example, after allergy testing."/>
  <jurisdiction>
    <coding>
      <system value="http://unstats.un.org/unsd/methods/m49/m49.htm"/>
      <code value="036"/>
      <display value="Australia (AUS)"/>
    </coding>
  </jurisdiction>
  <fhirVersion value="4.0.1"/>
  <kind value="logical"/>
  <abstract value="false"/>
  <type
        value="https://aehrc.csiro.au/fhir/logical-models/AdverseReactionRisk"/>
  <baseDefinition value="http://hl7.org/fhir/StructureDefinition/Base"/>
  <derivation value="specialization"/>
  <snapshot>
    <extension
               url="http://hl7.org/fhir/tools/StructureDefinition/snapshot-base-version">
      <valueString value="4.0.1"/>
    </extension>
    <element id="AdverseReactionRisk">
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier">
        <valueIdentifier>
          <system
                  value="https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2"/>
          <value value="at0000"/>
        </valueIdentifier>
      </extension>
      <extension
                 url="https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations">
        <valueString
                     value="Use to record a clinical assessment of a propensity for an adverse reaction upon future exposure to a specified substance or class of substances including, but not limited to, incipients and excipients in medicinal preparations, biological products, metal salts, and organic chemical compounds. 

This archetype is intended to provide a single place within the health record to document the propensity for the full range of reactions, from trivial to life-threatening:
- immune-mediated: Types I-IV (including allergic reactions and hypersensitivities); or 
- non-immune-mediated: including pseudo-allergic reactions, side effects, intolerances, and drug toxicities.
In clinical practice distinguishing between immune-mediated and non-immune-mediated reactions can be difficult. Identification of the type of reaction is not a proxy for seriousness or risk of harm to the patient.

Where a propensity is identified, information or evidence about one or more reaction events can be recorded using the CLUSTER.adverse_reaction_event archetype in the 'Reaction event summary' SLOT.

Identification of the severity of the manifestation of the reaction, recorded in the CLUSTER.adverse_reaction_event archetype, can inform the 'Criticality' of the adverse reaction risk. For example, experiencing anaphylaxis on first exposure to a substance would warrant setting a 'Criticality' of 'high', due to the high risk that anaphylaxis is likely to recur on second and subsequent exposures.

This archetype has been designed to allow the recording of information about a specific substance (amoxycillin, oysters, or bee sting venom) or, alternatively, a class of substance (e.g. Penicillins). If a class of substance is recorded, identification of the exact substance can be recorded on a per-reaction basis using the CLUSTER.adverse_reaction_event archetype.

Use to record information about the positive presence of the risk of an adverse reaction:
- to support the direct clinical care of an individual; 
- as part of a managed adverse reaction or allergy/intolerance list; 
- to support the exchange of information about the propensity and events related to adverse reactions; 
- to inform adverse reaction reporting; and 
- to assist with computerised knowledge-based activities such as clinical decision support and alerts.

The risk of an adverse reaction event or manifestation must always propose a causative substance or class of substance. If there is a degree of uncertainty that a specific substance is the cause, the level of uncertainty can be recorded using the ‘Verification status’ data element. If more than one possible substance may have caused a reaction/manifestation, each substance should be recorded using a separate instance of this adverse reaction risk archetype with the ‘Verification status’ set to an initial state of ‘Unconfirmed’ so that adverse reaction checking can be activated in clinical systems. If the substance is later proven not to be causal then the ‘Verification status’ can be modified to ‘Refuted’ - for example, after allergy testing."/>
      </extension>
      <extension
                 url="https://aehrc.csiro.au/fhir/StructureDefinition/note-misuse">
        <valueString
                     value="Not to be used for recording physiological reactions to physical agents, such as heat, cold, sunlight, vibration, exercise activity, by infectious agents or food contaminants. Use a specific archetype for EVALUATION.problem/diagnosis or CLUSTER.symptom/sign for this purpose.

Not to be used to record adverse events, including failures of clinical process, interventions or products. For example: abnormal use, incorrect dosage or maladministration of an agent or substance; mislabelling; harm or injury caused by an intervention or procedure; overdose/poisoning etc. Use a specific archetype for the purpose. 

Not to be used to record an adverse reaction where the substance is unknown. Use EVALUATION.problem_diagnosis or CLUSTER.symptom_sign to record as part of the health record until a possible substance is identified.

Not to be used to record reactions to transfusions of blood products. Use a specific archetype for this purpose. 

Not to be used for recording 'alerts'. Use EVALUATION.precaution, EVALUATION.contraindication or related archetypes for this purpose.

Not to be used for recording failed therapy.

Not to be used for the explicit recording of an absence (or negative presence) of a reaction to 'any substances' or to identified substances, for example ‘No known allergies or adverse reactions’ or ‘No known allergies to Penicillin’. Use the EVALUATION.exclusion_global or EVALUATION.exclusion_specific archetypes to express a positive statement of adverse reaction exclusion.

Not to be used for the explicit recording that no information was able to be obtained about the adverse reaction status of a patient. Use the EVALUATION.absence archetype to record that a positive statement that information was not able to be obtained, for example, if a non-cooperative patient refuses to answer questions."/>
      </extension>
      <extension
                 url="https://aehrc.csiro.au/fhir/StructureDefinition/note-purpose">
        <valueString
                     value="To record the clinical assessment of the propensity for an individual to experience an adverse reaction if exposed, or re-exposed, to a specified substance or class of substances."/>
      </extension>
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint">
        <valueString value="orientation:right"/>
      </extension>
      <path value="AdverseReactionRisk"/>
      <short value="Adverse Reaction Risk"/>
      <definition
                  value="Clinical assessment of the propensity for an individual to experience a harmful or undesirable physiological response if exposed, or re-exposed, to a substance."/>
      <comment
               value="**Purpose**

To record the clinical assessment of the propensity for an individual to experience an adverse reaction if exposed, or re-exposed, to a specified substance or class of substances.

**Misuse**

Not to be used for recording physiological reactions to physical agents, such as heat, cold, sunlight, vibration, exercise activity, by infectious agents or food contaminants. Use a specific archetype for EVALUATION.problem/diagnosis or CLUSTER.symptom/sign for this purpose.

Not to be used to record adverse events, including failures of clinical process, interventions or products. For example: abnormal use, incorrect dosage or maladministration of an agent or substance; mislabelling; harm or injury caused by an intervention or procedure; overdose/poisoning etc. Use a specific archetype for the purpose. 

Not to be used to record an adverse reaction where the substance is unknown. Use EVALUATION.problem_diagnosis or CLUSTER.symptom_sign to record as part of the health record until a possible substance is identified.

Not to be used to record reactions to transfusions of blood products. Use a specific archetype for this purpose. 

Not to be used for recording 'alerts'. Use EVALUATION.precaution, EVALUATION.contraindication or related archetypes for this purpose.

Not to be used for recording failed therapy.

Not to be used for the explicit recording of an absence (or negative presence) of a reaction to 'any substances' or to identified substances, for example ‘No known allergies or adverse reactions’ or ‘No known allergies to Penicillin’. Use the EVALUATION.exclusion_global or EVALUATION.exclusion_specific archetypes to express a positive statement of adverse reaction exclusion.

Not to be used for the explicit recording that no information was able to be obtained about the adverse reaction status of a patient. Use the EVALUATION.absence archetype to record that a positive statement that information was not able to be obtained, for example, if a non-cooperative patient refuses to answer questions.

**Considerations**

Use to record a clinical assessment of a propensity for an adverse reaction upon future exposure to a specified substance or class of substances including, but not limited to, incipients and excipients in medicinal preparations, biological products, metal salts, and organic chemical compounds. 

This archetype is intended to provide a single place within the health record to document the propensity for the full range of reactions, from trivial to life-threatening:
- immune-mediated: Types I-IV (including allergic reactions and hypersensitivities); or 
- non-immune-mediated: including pseudo-allergic reactions, side effects, intolerances, and drug toxicities.
In clinical practice distinguishing between immune-mediated and non-immune-mediated reactions can be difficult. Identification of the type of reaction is not a proxy for seriousness or risk of harm to the patient.

Where a propensity is identified, information or evidence about one or more reaction events can be recorded using the CLUSTER.adverse_reaction_event archetype in the 'Reaction event summary' SLOT.

Identification of the severity of the manifestation of the reaction, recorded in the CLUSTER.adverse_reaction_event archetype, can inform the 'Criticality' of the adverse reaction risk. For example, experiencing anaphylaxis on first exposure to a substance would warrant setting a 'Criticality' of 'high', due to the high risk that anaphylaxis is likely to recur on second and subsequent exposures.

This archetype has been designed to allow the recording of information about a specific substance (amoxycillin, oysters, or bee sting venom) or, alternatively, a class of substance (e.g. Penicillins). If a class of substance is recorded, identification of the exact substance can be recorded on a per-reaction basis using the CLUSTER.adverse_reaction_event archetype.

Use to record information about the positive presence of the risk of an adverse reaction:
- to support the direct clinical care of an individual; 
- as part of a managed adverse reaction or allergy/intolerance list; 
- to support the exchange of information about the propensity and events related to adverse reactions; 
- to inform adverse reaction reporting; and 
- to assist with computerised knowledge-based activities such as clinical decision support and alerts.

The risk of an adverse reaction event or manifestation must always propose a causative substance or class of substance. If there is a degree of uncertainty that a specific substance is the cause, the level of uncertainty can be recorded using the ‘Verification status’ data element. If more than one possible substance may have caused a reaction/manifestation, each substance should be recorded using a separate instance of this adverse reaction risk archetype with the ‘Verification status’ set to an initial state of ‘Unconfirmed’ so that adverse reaction checking can be activated in clinical systems. If the substance is later proven not to be causal then the ‘Verification status’ can be modified to ‘Refuted’ - for example, after allergy testing."/>
      <alias value="reaction"/>
      <min value="0"/>
      <max value="*"/>
      <base>
        <path value="Base"/>
        <min value="0"/>
        <max value="*"/>
      </base>
      <mustSupport value="true"/>
      <isModifier value="false"/>
    </element>
    <element id="AdverseReactionRisk.Protocol">
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier">
        <valueIdentifier>
          <system
                  value="https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2"/>
          <value value="protocol"/>
        </valueIdentifier>
      </extension>
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint">
        <valueString value="orientation:right"/>
      </extension>
      <path value="AdverseReactionRisk.Protocol"/>
      <short value="Protocol"/>
      <definition value="@ internal @"/>
      <min value="0"/>
      <max value="1"/>
      <base>
        <path value="AdverseReactionRisk.Protocol"/>
        <min value="0"/>
        <max value="1"/>
      </base>
      <type>
        <code value="BackboneElement"/>
      </type>
      <constraint>
        <key value="ele-1"/>
        <severity value="error"/>
        <human value="All FHIR elements must have a @value or children"/>
        <expression
                    value="hasValue() or (children().count() &gt; id.count())"/>
        <xpath value="@value|f:*|h:div"/>
        <source value="http://hl7.org/fhir/StructureDefinition/Element"/>
      </constraint>
      <mustSupport value="true"/>
    </element>
    <element id="AdverseReactionRisk.Protocol.id">
      <path value="AdverseReactionRisk.Protocol.id"/>
      <representation value="xmlAttr"/>
      <short value="Unique id for inter-element referencing"/>
      <definition
                  value="Unique id for the element within a resource (for internal references). This may be any string value that does not contain spaces."/>
      <min value="0"/>
      <max value="1"/>
      <base>
        <path value="Element.id"/>
        <min value="0"/>
        <max value="1"/>
      </base>
      <type>
        <extension
                   url="http://hl7.org/fhir/StructureDefinition/structuredefinition-fhir-type">
          <valueUrl value="string"/>
        </extension>
        <code value="http://hl7.org/fhirpath/System.String"/>
      </type>
      <isModifier value="false"/>
      <isSummary value="false"/>
      <mapping>
        <identity value="rim"/>
        <map value="n/a"/>
      </mapping>
    </element>
    <element id="AdverseReactionRisk.Protocol.extension">
      <path value="AdverseReactionRisk.Protocol.extension"/>
      <slicing>
        <discriminator>
          <type value="value"/>
          <path value="url"/>
        </discriminator>
        <description value="Extensions are always sliced by (at least) url"/>
        <rules value="open"/>
      </slicing>
      <short value="Additional content defined by implementations"/>
      <definition
                  value="May be used to represent additional information that is not part of the basic definition of the element. To make the use of extensions safe and manageable, there is a strict set of governance  applied to the definition and use of extensions. Though any implementer can define an extension, there is a set of requirements that SHALL be met as part of the definition of the extension."/>
      <comment
               value="There can be no stigma associated with the use of extensions by any application, project, or standard - regardless of the institution or jurisdiction that uses or defines the extensions.  The use of extensions is what allows the FHIR specification to retain a core level of simplicity for everyone."/>
      <alias value="extensions"/>
      <alias value="user content"/>
      <min value="0"/>
      <max value="*"/>
      <base>
        <path value="Element.extension"/>
        <min value="0"/>
        <max value="*"/>
      </base>
      <type>
        <code value="Extension"/>
      </type>
      <constraint>
        <key value="ele-1"/>
        <severity value="error"/>
        <human value="All FHIR elements must have a @value or children"/>
        <expression
                    value="hasValue() or (children().count() &gt; id.count())"/>
        <xpath value="@value|f:*|h:div"/>
        <source value="http://hl7.org/fhir/StructureDefinition/Element"/>
      </constraint>
      <constraint>
        <key value="ext-1"/>
        <severity value="error"/>
        <human value="Must have either extensions or value[x], not both"/>
        <expression value="extension.exists() != value.exists()"/>
        <xpath
               value="exists(f:extension)!=exists(f:*[starts-with(local-name(.), &quot;value&quot;)])"/>
        <source value="http://hl7.org/fhir/StructureDefinition/Extension"/>
      </constraint>
      <isModifier value="false"/>
      <isSummary value="false"/>
      <mapping>
        <identity value="rim"/>
        <map value="n/a"/>
      </mapping>
    </element>
    <element id="AdverseReactionRisk.Protocol.modifierExtension">
      <path value="AdverseReactionRisk.Protocol.modifierExtension"/>
      <short value="Extensions that cannot be ignored even if unrecognized"/>
      <definition
                  value="May be used to represent additional information that is not part of the basic definition of the element and that modifies the understanding of the element in which it is contained and/or the understanding of the containing element's descendants. Usually modifier elements provide negation or qualification. To make the use of extensions safe and manageable, there is a strict set of governance applied to the definition and use of extensions. Though any implementer can define an extension, there is a set of requirements that SHALL be met as part of the definition of the extension. Applications processing a resource are required to check for modifier extensions.

Modifier extensions SHALL NOT change the meaning of any elements on Resource or DomainResource (including cannot change the meaning of modifierExtension itself)."/>
      <comment
               value="There can be no stigma associated with the use of extensions by any application, project, or standard - regardless of the institution or jurisdiction that uses or defines the extensions.  The use of extensions is what allows the FHIR specification to retain a core level of simplicity for everyone."/>
      <requirements
                    value="Modifier extensions allow for extensions that *cannot* be safely ignored to be clearly distinguished from the vast majority of extensions which can be safely ignored.  This promotes interoperability by eliminating the need for implementers to prohibit the presence of extensions. For further information, see the [definition of modifier extensions](http://hl7.org/fhir/R4/extensibility.html#modifierExtension)."/>
      <alias value="extensions"/>
      <alias value="user content"/>
      <alias value="modifiers"/>
      <min value="0"/>
      <max value="*"/>
      <base>
        <path value="BackboneElement.modifierExtension"/>
        <min value="0"/>
        <max value="*"/>
      </base>
      <type>
        <code value="Extension"/>
      </type>
      <constraint>
        <key value="ele-1"/>
        <severity value="error"/>
        <human value="All FHIR elements must have a @value or children"/>
        <expression
                    value="hasValue() or (children().count() &gt; id.count())"/>
        <xpath value="@value|f:*|h:div"/>
        <source value="http://hl7.org/fhir/StructureDefinition/Element"/>
      </constraint>
      <constraint>
        <key value="ext-1"/>
        <severity value="error"/>
        <human value="Must have either extensions or value[x], not both"/>
        <expression value="extension.exists() != value.exists()"/>
        <xpath
               value="exists(f:extension)!=exists(f:*[starts-with(local-name(.), &quot;value&quot;)])"/>
        <source value="http://hl7.org/fhir/StructureDefinition/Extension"/>
      </constraint>
      <isModifier value="true"/>
      <isModifierReason
                        value="Modifier extensions are expected to modify the meaning or interpretation of the element that contains them"/>
      <isSummary value="true"/>
      <mapping>
        <identity value="rim"/>
        <map value="N/A"/>
      </mapping>
    </element>
    <element id="AdverseReactionRisk.Protocol.Lastupdated">
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier">
        <valueIdentifier>
          <system
                  value="https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2"/>
          <value value="at0062"/>
        </valueIdentifier>
      </extension>
      <path value="AdverseReactionRisk.Protocol.Lastupdated"/>
      <short value="Last updated"/>
      <definition
                  value="Date when the propensity or the reaction event was updated."/>
      <min value="0"/>
      <max value="1"/>
      <base>
        <path value="AdverseReactionRisk.Protocol.Lastupdated"/>
        <min value="0"/>
        <max value="1"/>
      </base>
      <type>
        <code value="dateTime"/>
      </type>
      <mustSupport value="true"/>
    </element>
    <element id="AdverseReactionRisk.Protocol.Extension">
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier">
        <valueIdentifier>
          <system
                  value="https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2"/>
          <value value="at0128"/>
        </valueIdentifier>
      </extension>
      <extension
                 url="https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations">
        <valueString
                     value="For example: local information requirements or additional metadata to align with FHIR equivalents."/>
      </extension>
      <path value="AdverseReactionRisk.Protocol.Extension"/>
      <short value="Extension"/>
      <definition
                  value="Additional information required to capture local content or to align with other reference models/formalisms."/>
      <comment
               value="**Considerations**

For example: local information requirements or additional metadata to align with FHIR equivalents."/>
      <min value="0"/>
      <max value="1"/>
      <base>
        <path value="AdverseReactionRisk.Protocol.Extension"/>
        <min value="0"/>
        <max value="1"/>
      </base>
      <type>
        <code value="Reference"/>
      </type>
      <mustSupport value="true"/>
    </element>
    <element id="AdverseReactionRisk.Data">
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier">
        <valueIdentifier>
          <system
                  value="https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2"/>
          <value value="data"/>
        </valueIdentifier>
      </extension>
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint">
        <valueString value="orientation:right"/>
      </extension>
      <path value="AdverseReactionRisk.Data"/>
      <short value="Data"/>
      <definition value="@ internal @"/>
      <min value="0"/>
      <max value="1"/>
      <base>
        <path value="AdverseReactionRisk.Data"/>
        <min value="0"/>
        <max value="1"/>
      </base>
      <type>
        <code value="BackboneElement"/>
      </type>
      <constraint>
        <key value="ele-1"/>
        <severity value="error"/>
        <human value="All FHIR elements must have a @value or children"/>
        <expression
                    value="hasValue() or (children().count() &gt; id.count())"/>
        <xpath value="@value|f:*|h:div"/>
        <source value="http://hl7.org/fhir/StructureDefinition/Element"/>
      </constraint>
      <mustSupport value="true"/>
    </element>
    <element id="AdverseReactionRisk.Data.id">
      <path value="AdverseReactionRisk.Data.id"/>
      <representation value="xmlAttr"/>
      <short value="Unique id for inter-element referencing"/>
      <definition
                  value="Unique id for the element within a resource (for internal references). This may be any string value that does not contain spaces."/>
      <min value="0"/>
      <max value="1"/>
      <base>
        <path value="Element.id"/>
        <min value="0"/>
        <max value="1"/>
      </base>
      <type>
        <extension
                   url="http://hl7.org/fhir/StructureDefinition/structuredefinition-fhir-type">
          <valueUrl value="string"/>
        </extension>
        <code value="http://hl7.org/fhirpath/System.String"/>
      </type>
      <isModifier value="false"/>
      <isSummary value="false"/>
      <mapping>
        <identity value="rim"/>
        <map value="n/a"/>
      </mapping>
    </element>
    <element id="AdverseReactionRisk.Data.extension">
      <path value="AdverseReactionRisk.Data.extension"/>
      <slicing>
        <discriminator>
          <type value="value"/>
          <path value="url"/>
        </discriminator>
        <description value="Extensions are always sliced by (at least) url"/>
        <rules value="open"/>
      </slicing>
      <short value="Additional content defined by implementations"/>
      <definition
                  value="May be used to represent additional information that is not part of the basic definition of the element. To make the use of extensions safe and manageable, there is a strict set of governance  applied to the definition and use of extensions. Though any implementer can define an extension, there is a set of requirements that SHALL be met as part of the definition of the extension."/>
      <comment
               value="There can be no stigma associated with the use of extensions by any application, project, or standard - regardless of the institution or jurisdiction that uses or defines the extensions.  The use of extensions is what allows the FHIR specification to retain a core level of simplicity for everyone."/>
      <alias value="extensions"/>
      <alias value="user content"/>
      <min value="0"/>
      <max value="*"/>
      <base>
        <path value="Element.extension"/>
        <min value="0"/>
        <max value="*"/>
      </base>
      <type>
        <code value="Extension"/>
      </type>
      <constraint>
        <key value="ele-1"/>
        <severity value="error"/>
        <human value="All FHIR elements must have a @value or children"/>
        <expression
                    value="hasValue() or (children().count() &gt; id.count())"/>
        <xpath value="@value|f:*|h:div"/>
        <source value="http://hl7.org/fhir/StructureDefinition/Element"/>
      </constraint>
      <constraint>
        <key value="ext-1"/>
        <severity value="error"/>
        <human value="Must have either extensions or value[x], not both"/>
        <expression value="extension.exists() != value.exists()"/>
        <xpath
               value="exists(f:extension)!=exists(f:*[starts-with(local-name(.), &quot;value&quot;)])"/>
        <source value="http://hl7.org/fhir/StructureDefinition/Extension"/>
      </constraint>
      <isModifier value="false"/>
      <isSummary value="false"/>
      <mapping>
        <identity value="rim"/>
        <map value="n/a"/>
      </mapping>
    </element>
    <element id="AdverseReactionRisk.Data.modifierExtension">
      <path value="AdverseReactionRisk.Data.modifierExtension"/>
      <short value="Extensions that cannot be ignored even if unrecognized"/>
      <definition
                  value="May be used to represent additional information that is not part of the basic definition of the element and that modifies the understanding of the element in which it is contained and/or the understanding of the containing element's descendants. Usually modifier elements provide negation or qualification. To make the use of extensions safe and manageable, there is a strict set of governance applied to the definition and use of extensions. Though any implementer can define an extension, there is a set of requirements that SHALL be met as part of the definition of the extension. Applications processing a resource are required to check for modifier extensions.

Modifier extensions SHALL NOT change the meaning of any elements on Resource or DomainResource (including cannot change the meaning of modifierExtension itself)."/>
      <comment
               value="There can be no stigma associated with the use of extensions by any application, project, or standard - regardless of the institution or jurisdiction that uses or defines the extensions.  The use of extensions is what allows the FHIR specification to retain a core level of simplicity for everyone."/>
      <requirements
                    value="Modifier extensions allow for extensions that *cannot* be safely ignored to be clearly distinguished from the vast majority of extensions which can be safely ignored.  This promotes interoperability by eliminating the need for implementers to prohibit the presence of extensions. For further information, see the [definition of modifier extensions](http://hl7.org/fhir/R4/extensibility.html#modifierExtension)."/>
      <alias value="extensions"/>
      <alias value="user content"/>
      <alias value="modifiers"/>
      <min value="0"/>
      <max value="*"/>
      <base>
        <path value="BackboneElement.modifierExtension"/>
        <min value="0"/>
        <max value="*"/>
      </base>
      <type>
        <code value="Extension"/>
      </type>
      <constraint>
        <key value="ele-1"/>
        <severity value="error"/>
        <human value="All FHIR elements must have a @value or children"/>
        <expression
                    value="hasValue() or (children().count() &gt; id.count())"/>
        <xpath value="@value|f:*|h:div"/>
        <source value="http://hl7.org/fhir/StructureDefinition/Element"/>
      </constraint>
      <constraint>
        <key value="ext-1"/>
        <severity value="error"/>
        <human value="Must have either extensions or value[x], not both"/>
        <expression value="extension.exists() != value.exists()"/>
        <xpath
               value="exists(f:extension)!=exists(f:*[starts-with(local-name(.), &quot;value&quot;)])"/>
        <source value="http://hl7.org/fhir/StructureDefinition/Extension"/>
      </constraint>
      <isModifier value="true"/>
      <isModifierReason
                        value="Modifier extensions are expected to modify the meaning or interpretation of the element that contains them"/>
      <isSummary value="true"/>
      <mapping>
        <identity value="rim"/>
        <map value="N/A"/>
      </mapping>
    </element>
    <element id="AdverseReactionRisk.Data.Substance">
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier">
        <valueIdentifier>
          <system
                  value="https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2"/>
          <value value="at0002"/>
        </valueIdentifier>
      </extension>
      <extension
                 url="https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations">
        <valueString
                     value="Both an individual substance and a substance class are valid entries in 'Substance'. A substance may be a compound of simpler substances, for example a medicinal product. It is strongly recommended that the 'Substance' is coded with a terminology capable of triggering decision support, where possible. For example: Snomed CT, DM+D, RxNorm, NDFRT, ATC, New Zealand Universal List of Medicines and Australian Medicines Terminology. Free text entry should only be used if there is no appropriate terminology available."/>
      </extension>
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint">
        <valueString value="orientation:right"/>
      </extension>
      <path value="AdverseReactionRisk.Data.Substance"/>
      <short value="Substance"/>
      <definition
                  value="Identification of a substance, or substance class, that is considered to put the individual at risk of an adverse reaction event."/>
      <comment
               value="**Considerations**

Both an individual substance and a substance class are valid entries in 'Substance'. A substance may be a compound of simpler substances, for example a medicinal product. It is strongly recommended that the 'Substance' is coded with a terminology capable of triggering decision support, where possible. For example: Snomed CT, DM+D, RxNorm, NDFRT, ATC, New Zealand Universal List of Medicines and Australian Medicines Terminology. Free text entry should only be used if there is no appropriate terminology available."/>
      <min value="1"/>
      <max value="1"/>
      <base>
        <path value="AdverseReactionRisk.Data.Substance"/>
        <min value="1"/>
        <max value="1"/>
      </base>
      <type>
        <code value="CodeableConcept"/>
      </type>
      <mustSupport value="true"/>
    </element>
    <element id="AdverseReactionRisk.Data.Activeinactivestatus">
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier">
        <valueIdentifier>
          <system
                  value="https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2"/>
          <value value="at0130"/>
        </valueIdentifier>
      </extension>
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint">
        <valueString value="orientation:right"/>
      </extension>
      <path value="AdverseReactionRisk.Data.Activeinactivestatus"/>
      <short value="Activeinactivestatus"/>
      <definition
                  value="Status about whether the adverse reaction risk statement is active or inactive."/>
      <min value="0"/>
      <max value="1"/>
      <base>
        <path value="AdverseReactionRisk.Data.Activeinactivestatus"/>
        <min value="0"/>
        <max value="1"/>
      </base>
      <type>
        <code value="Coding"/>
      </type>
      <mustSupport value="true"/>
    </element>
    <element id="AdverseReactionRisk.Data.Verificationstatus">
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier">
        <valueIdentifier>
          <system
                  value="https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2"/>
          <value value="at0063"/>
        </valueIdentifier>
      </extension>
      <extension
                 url="https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations">
        <valueString
                     value="Decision support would typically raise alerts for 'Unconfirmed' and 'Confirmed', and ignore a 'Refuted' reaction. Clinical systems may choose not to display Adverse reaction entries with a 'Refuted' status in the Adverse Reaction List. However, 'Refuted' may be useful for reconciliation of the adverse reaction list or when communicating between systems. Some implementations may choose to make this field mandatory. The free text data type will allow for local variation by enabling other value sets to be applied to this data element in a template - in this situation it is recommended that values should be coded using a terminology."/>
      </extension>
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint">
        <valueString value="orientation:right"/>
      </extension>
      <path value="AdverseReactionRisk.Data.Verificationstatus"/>
      <short value="Verification status"/>
      <definition
                  value="Assertion about the certainty of the propensity, or potential future risk, of the identified 'Substance' to cause a reaction."/>
      <comment
               value="**Considerations**

Decision support would typically raise alerts for 'Unconfirmed' and 'Confirmed', and ignore a 'Refuted' reaction. Clinical systems may choose not to display Adverse reaction entries with a 'Refuted' status in the Adverse Reaction List. However, 'Refuted' may be useful for reconciliation of the adverse reaction list or when communicating between systems. Some implementations may choose to make this field mandatory. The free text data type will allow for local variation by enabling other value sets to be applied to this data element in a template - in this situation it is recommended that values should be coded using a terminology."/>
      <min value="0"/>
      <max value="1"/>
      <base>
        <path value="AdverseReactionRisk.Data.Verificationstatus"/>
        <min value="0"/>
        <max value="1"/>
      </base>
      <type>
        <code value="Coding"/>
      </type>
      <mustSupport value="true"/>
    </element>
    <element id="AdverseReactionRisk.Data.Criticality">
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier">
        <valueIdentifier>
          <system
                  value="https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2"/>
          <value value="at0101"/>
        </valueIdentifier>
      </extension>
      <extension
                 url="https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations">
        <valueString
                     value="This can be regarded as a predictive judgement of a 'worst case scenario'. In most contexts 'Low' would be regarded as the default value."/>
      </extension>
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint">
        <valueString value="orientation:right"/>
      </extension>
      <path value="AdverseReactionRisk.Data.Criticality"/>
      <short value="Criticality"/>
      <definition
                  value="An indication of the potential for critical system organ damage or life threatening consequence."/>
      <comment
               value="**Considerations**

This can be regarded as a predictive judgement of a 'worst case scenario'. In most contexts 'Low' would be regarded as the default value."/>
      <min value="0"/>
      <max value="1"/>
      <base>
        <path value="AdverseReactionRisk.Data.Criticality"/>
        <min value="0"/>
        <max value="1"/>
      </base>
      <type>
        <code value="CodeableConcept"/>
      </type>
      <mustSupport value="true"/>
    </element>
    <element id="AdverseReactionRisk.Data.Category">
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier">
        <valueIdentifier>
          <system
                  value="https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2"/>
          <value value="at0120"/>
        </valueIdentifier>
      </extension>
      <extension
                 url="https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations">
        <valueString
                     value="This data element has been included because it is currently being captured in some clinical systems. This data can be derived from the Substance where coding systems are used, and is effectively redundant in that situation."/>
      </extension>
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint">
        <valueString value="orientation:right"/>
      </extension>
      <path value="AdverseReactionRisk.Data.Category"/>
      <short value="Category"/>
      <definition value="Category of the identified 'Substance'."/>
      <comment
               value="**Considerations**

This data element has been included because it is currently being captured in some clinical systems. This data can be derived from the Substance where coding systems are used, and is effectively redundant in that situation."/>
      <min value="0"/>
      <max value="1"/>
      <base>
        <path value="AdverseReactionRisk.Data.Category"/>
        <min value="0"/>
        <max value="1"/>
      </base>
      <type>
        <code value="CodeableConcept"/>
      </type>
      <mustSupport value="true"/>
    </element>
    <element id="AdverseReactionRisk.Data.Onsetoflastreaction">
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier">
        <valueIdentifier>
          <system
                  value="https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2"/>
          <value value="at0117"/>
        </valueIdentifier>
      </extension>
      <extension
                 url="https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations">
        <valueString
                     value="For example: the actual date and/or time of onset; the interval of time during which the onset occurred; the age of the individual at the time of the onset; or the duration of time since the onset occurred. A partial date is valid, using the DV_DATE_TIME data type, to record only a year."/>
      </extension>
      <path value="AdverseReactionRisk.Data.Onsetoflastreaction"/>
      <short value="Onset of last reaction"/>
      <definition
                  value="The date and/or time of the onset of the last known occurrence of a reaction event."/>
      <comment
               value="**Considerations**

For example: the actual date and/or time of onset; the interval of time during which the onset occurred; the age of the individual at the time of the onset; or the duration of time since the onset occurred. A partial date is valid, using the DV_DATE_TIME data type, to record only a year."/>
      <min value="0"/>
      <max value="1"/>
      <base>
        <path value="AdverseReactionRisk.Data.Onsetoflastreaction"/>
        <min value="0"/>
        <max value="1"/>
      </base>
      <type>
        <code value="dateTime"/>
      </type>
      <type>
        <code value="string"/>
      </type>
      <mustSupport value="true"/>
    </element>
    <element id="AdverseReactionRisk.Data.Onsetoffirstreaction">
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier">
        <valueIdentifier>
          <system
                  value="https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2"/>
          <value value="at0133"/>
        </valueIdentifier>
      </extension>
      <extension
                 url="https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations">
        <valueString
                     value="For example: the actual date and/or time of onset; the interval of time during which the onset occurred; the age of the individual at the time of the onset; or the duration of time since the onset occurred. A partial date is valid, using the DV_DATE_TIME data type, to record only a year."/>
      </extension>
      <path value="AdverseReactionRisk.Data.Onsetoffirstreaction"/>
      <short value="Onset of first reaction"/>
      <definition
                  value="The onset of the first known occurrence of a reaction event."/>
      <comment
               value="**Considerations**

For example: the actual date and/or time of onset; the interval of time during which the onset occurred; the age of the individual at the time of the onset; or the duration of time since the onset occurred. A partial date is valid, using the DV_DATE_TIME data type, to record only a year."/>
      <min value="0"/>
      <max value="1"/>
      <base>
        <path value="AdverseReactionRisk.Data.Onsetoffirstreaction"/>
        <min value="0"/>
        <max value="1"/>
      </base>
      <type>
        <code value="dateTime"/>
      </type>
      <type>
        <code value="string"/>
      </type>
      <mustSupport value="true"/>
    </element>
    <element id="AdverseReactionRisk.Data.Reactionmechanism">
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier">
        <valueIdentifier>
          <system
                  value="https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2"/>
          <value value="at0058"/>
        </valueIdentifier>
      </extension>
      <extension
                 url="https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations">
        <valueString
                     value="Immune-mediated responses have been traditionally regarded as an indicator for escalation of significant future risk. Contemporary knowledge suggests that some reactions previously thought to be immune are actually non-immune and still carry life threatening risk. 

Immunological testing may provide supporting evidence for the mechanism and causative substance , but no tests are 100% sensitive or specific for a sensitivity. 

It is acknowledged that most clinicians will NOT be able to distinguish the mechanism of any specific reaction. However this data element is included because many legacy systems have captured this attribute."/>
      </extension>
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint">
        <valueString value="orientation:right"/>
      </extension>
      <path value="AdverseReactionRisk.Data.Reactionmechanism"/>
      <short value="Reaction mechanism"/>
      <definition
                  value="Identification of the underlying physiological mechanism for the adverse reaction."/>
      <comment
               value="**Considerations**

Immune-mediated responses have been traditionally regarded as an indicator for escalation of significant future risk. Contemporary knowledge suggests that some reactions previously thought to be immune are actually non-immune and still carry life threatening risk. 

Immunological testing may provide supporting evidence for the mechanism and causative substance , but no tests are 100% sensitive or specific for a sensitivity. 

It is acknowledged that most clinicians will NOT be able to distinguish the mechanism of any specific reaction. However this data element is included because many legacy systems have captured this attribute."/>
      <min value="0"/>
      <max value="1"/>
      <base>
        <path value="AdverseReactionRisk.Data.Reactionmechanism"/>
        <min value="0"/>
        <max value="1"/>
      </base>
      <type>
        <code value="CodeableConcept"/>
      </type>
      <mustSupport value="true"/>
    </element>
    <element id="AdverseReactionRisk.Data.Reactioneventsummary">
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier">
        <valueIdentifier>
          <system
                  value="https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2"/>
          <value value="at0129"/>
        </valueIdentifier>
      </extension>
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint">
        <valueString value="orientation:right"/>
      </extension>
      <path value="AdverseReactionRisk.Data.Reactioneventsummary"/>
      <short value="Reaction event summary"/>
      <definition
                  value="Summary details about each adverse reaction event linked to exposure to the identified 'Substance'."/>
      <min value="0"/>
      <max value="*"/>
      <base>
        <path value="AdverseReactionRisk.Data.Reactioneventsummary"/>
        <min value="0"/>
        <max value="*"/>
      </base>
      <type>
        <code value="Reference"/>
        <targetProfile
                       value="https://aehrc.csiro.au/fhir/logical-models/AdverseReactionEvent"/>
      </type>
      <mustSupport value="true"/>
    </element>
    <element id="AdverseReactionRisk.Data.Comment">
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier">
        <valueIdentifier>
          <system
                  value="https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2"/>
          <value value="at0006"/>
        </valueIdentifier>
      </extension>
      <extension
                 url="https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations">
        <valueString
                     value="For example: including reason for flagging a 'Criticality' of 'High risk'; and instructions related to future exposure or administration of the Substance, such as administration within an Intensive Care Unit or under corticosteroid cover."/>
      </extension>
      <path value="AdverseReactionRisk.Data.Comment"/>
      <short value="Comment"/>
      <definition
                  value="Additional narrative about the propensity for the adverse reaction, not captured in other fields."/>
      <comment
               value="**Considerations**

For example: including reason for flagging a 'Criticality' of 'High risk'; and instructions related to future exposure or administration of the Substance, such as administration within an Intensive Care Unit or under corticosteroid cover."/>
      <min value="0"/>
      <max value="1"/>
      <base>
        <path value="AdverseReactionRisk.Data.Comment"/>
        <min value="0"/>
        <max value="1"/>
      </base>
      <type>
        <code value="string"/>
      </type>
      <mustSupport value="true"/>
    </element>
  </snapshot>
  <differential>
    <element id="AdverseReactionRisk">
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier">
        <valueIdentifier>
          <system
                  value="https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2"/>
          <value value="at0000"/>
        </valueIdentifier>
      </extension>
      <extension
                 url="https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations">
        <valueString
                     value="Use to record a clinical assessment of a propensity for an adverse reaction upon future exposure to a specified substance or class of substances including, but not limited to, incipients and excipients in medicinal preparations, biological products, metal salts, and organic chemical compounds. 

This archetype is intended to provide a single place within the health record to document the propensity for the full range of reactions, from trivial to life-threatening:
- immune-mediated: Types I-IV (including allergic reactions and hypersensitivities); or 
- non-immune-mediated: including pseudo-allergic reactions, side effects, intolerances, and drug toxicities.
In clinical practice distinguishing between immune-mediated and non-immune-mediated reactions can be difficult. Identification of the type of reaction is not a proxy for seriousness or risk of harm to the patient.

Where a propensity is identified, information or evidence about one or more reaction events can be recorded using the CLUSTER.adverse_reaction_event archetype in the 'Reaction event summary' SLOT.

Identification of the severity of the manifestation of the reaction, recorded in the CLUSTER.adverse_reaction_event archetype, can inform the 'Criticality' of the adverse reaction risk. For example, experiencing anaphylaxis on first exposure to a substance would warrant setting a 'Criticality' of 'high', due to the high risk that anaphylaxis is likely to recur on second and subsequent exposures.

This archetype has been designed to allow the recording of information about a specific substance (amoxycillin, oysters, or bee sting venom) or, alternatively, a class of substance (e.g. Penicillins). If a class of substance is recorded, identification of the exact substance can be recorded on a per-reaction basis using the CLUSTER.adverse_reaction_event archetype.

Use to record information about the positive presence of the risk of an adverse reaction:
- to support the direct clinical care of an individual; 
- as part of a managed adverse reaction or allergy/intolerance list; 
- to support the exchange of information about the propensity and events related to adverse reactions; 
- to inform adverse reaction reporting; and 
- to assist with computerised knowledge-based activities such as clinical decision support and alerts.

The risk of an adverse reaction event or manifestation must always propose a causative substance or class of substance. If there is a degree of uncertainty that a specific substance is the cause, the level of uncertainty can be recorded using the ‘Verification status’ data element. If more than one possible substance may have caused a reaction/manifestation, each substance should be recorded using a separate instance of this adverse reaction risk archetype with the ‘Verification status’ set to an initial state of ‘Unconfirmed’ so that adverse reaction checking can be activated in clinical systems. If the substance is later proven not to be causal then the ‘Verification status’ can be modified to ‘Refuted’ - for example, after allergy testing."/>
      </extension>
      <extension
                 url="https://aehrc.csiro.au/fhir/StructureDefinition/note-misuse">
        <valueString
                     value="Not to be used for recording physiological reactions to physical agents, such as heat, cold, sunlight, vibration, exercise activity, by infectious agents or food contaminants. Use a specific archetype for EVALUATION.problem/diagnosis or CLUSTER.symptom/sign for this purpose.

Not to be used to record adverse events, including failures of clinical process, interventions or products. For example: abnormal use, incorrect dosage or maladministration of an agent or substance; mislabelling; harm or injury caused by an intervention or procedure; overdose/poisoning etc. Use a specific archetype for the purpose. 

Not to be used to record an adverse reaction where the substance is unknown. Use EVALUATION.problem_diagnosis or CLUSTER.symptom_sign to record as part of the health record until a possible substance is identified.

Not to be used to record reactions to transfusions of blood products. Use a specific archetype for this purpose. 

Not to be used for recording 'alerts'. Use EVALUATION.precaution, EVALUATION.contraindication or related archetypes for this purpose.

Not to be used for recording failed therapy.

Not to be used for the explicit recording of an absence (or negative presence) of a reaction to 'any substances' or to identified substances, for example ‘No known allergies or adverse reactions’ or ‘No known allergies to Penicillin’. Use the EVALUATION.exclusion_global or EVALUATION.exclusion_specific archetypes to express a positive statement of adverse reaction exclusion.

Not to be used for the explicit recording that no information was able to be obtained about the adverse reaction status of a patient. Use the EVALUATION.absence archetype to record that a positive statement that information was not able to be obtained, for example, if a non-cooperative patient refuses to answer questions."/>
      </extension>
      <extension
                 url="https://aehrc.csiro.au/fhir/StructureDefinition/note-purpose">
        <valueString
                     value="To record the clinical assessment of the propensity for an individual to experience an adverse reaction if exposed, or re-exposed, to a specified substance or class of substances."/>
      </extension>
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint">
        <valueString value="orientation:right"/>
      </extension>
      <path value="AdverseReactionRisk"/>
      <short value="Adverse Reaction Risk"/>
      <definition
                  value="Clinical assessment of the propensity for an individual to experience a harmful or undesirable physiological response if exposed, or re-exposed, to a substance."/>
      <comment
               value="**Purpose**

To record the clinical assessment of the propensity for an individual to experience an adverse reaction if exposed, or re-exposed, to a specified substance or class of substances.

**Misuse**

Not to be used for recording physiological reactions to physical agents, such as heat, cold, sunlight, vibration, exercise activity, by infectious agents or food contaminants. Use a specific archetype for EVALUATION.problem/diagnosis or CLUSTER.symptom/sign for this purpose.

Not to be used to record adverse events, including failures of clinical process, interventions or products. For example: abnormal use, incorrect dosage or maladministration of an agent or substance; mislabelling; harm or injury caused by an intervention or procedure; overdose/poisoning etc. Use a specific archetype for the purpose. 

Not to be used to record an adverse reaction where the substance is unknown. Use EVALUATION.problem_diagnosis or CLUSTER.symptom_sign to record as part of the health record until a possible substance is identified.

Not to be used to record reactions to transfusions of blood products. Use a specific archetype for this purpose. 

Not to be used for recording 'alerts'. Use EVALUATION.precaution, EVALUATION.contraindication or related archetypes for this purpose.

Not to be used for recording failed therapy.

Not to be used for the explicit recording of an absence (or negative presence) of a reaction to 'any substances' or to identified substances, for example ‘No known allergies or adverse reactions’ or ‘No known allergies to Penicillin’. Use the EVALUATION.exclusion_global or EVALUATION.exclusion_specific archetypes to express a positive statement of adverse reaction exclusion.

Not to be used for the explicit recording that no information was able to be obtained about the adverse reaction status of a patient. Use the EVALUATION.absence archetype to record that a positive statement that information was not able to be obtained, for example, if a non-cooperative patient refuses to answer questions.

**Considerations**

Use to record a clinical assessment of a propensity for an adverse reaction upon future exposure to a specified substance or class of substances including, but not limited to, incipients and excipients in medicinal preparations, biological products, metal salts, and organic chemical compounds. 

This archetype is intended to provide a single place within the health record to document the propensity for the full range of reactions, from trivial to life-threatening:
- immune-mediated: Types I-IV (including allergic reactions and hypersensitivities); or 
- non-immune-mediated: including pseudo-allergic reactions, side effects, intolerances, and drug toxicities.
In clinical practice distinguishing between immune-mediated and non-immune-mediated reactions can be difficult. Identification of the type of reaction is not a proxy for seriousness or risk of harm to the patient.

Where a propensity is identified, information or evidence about one or more reaction events can be recorded using the CLUSTER.adverse_reaction_event archetype in the 'Reaction event summary' SLOT.

Identification of the severity of the manifestation of the reaction, recorded in the CLUSTER.adverse_reaction_event archetype, can inform the 'Criticality' of the adverse reaction risk. For example, experiencing anaphylaxis on first exposure to a substance would warrant setting a 'Criticality' of 'high', due to the high risk that anaphylaxis is likely to recur on second and subsequent exposures.

This archetype has been designed to allow the recording of information about a specific substance (amoxycillin, oysters, or bee sting venom) or, alternatively, a class of substance (e.g. Penicillins). If a class of substance is recorded, identification of the exact substance can be recorded on a per-reaction basis using the CLUSTER.adverse_reaction_event archetype.

Use to record information about the positive presence of the risk of an adverse reaction:
- to support the direct clinical care of an individual; 
- as part of a managed adverse reaction or allergy/intolerance list; 
- to support the exchange of information about the propensity and events related to adverse reactions; 
- to inform adverse reaction reporting; and 
- to assist with computerised knowledge-based activities such as clinical decision support and alerts.

The risk of an adverse reaction event or manifestation must always propose a causative substance or class of substance. If there is a degree of uncertainty that a specific substance is the cause, the level of uncertainty can be recorded using the ‘Verification status’ data element. If more than one possible substance may have caused a reaction/manifestation, each substance should be recorded using a separate instance of this adverse reaction risk archetype with the ‘Verification status’ set to an initial state of ‘Unconfirmed’ so that adverse reaction checking can be activated in clinical systems. If the substance is later proven not to be causal then the ‘Verification status’ can be modified to ‘Refuted’ - for example, after allergy testing."/>
      <alias value="reaction"/>
      <min value="0"/>
      <max value="*"/>
      <mustSupport value="true"/>
    </element>
    <element id="AdverseReactionRisk.Protocol">
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier">
        <valueIdentifier>
          <system
                  value="https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2"/>
          <value value="protocol"/>
        </valueIdentifier>
      </extension>
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint">
        <valueString value="orientation:right"/>
      </extension>
      <path value="AdverseReactionRisk.Protocol"/>
      <short value="Protocol"/>
      <definition value="@ internal @"/>
      <min value="0"/>
      <max value="1"/>
      <type>
        <code value="BackboneElement"/>
      </type>
      <mustSupport value="true"/>
    </element>
    <element id="AdverseReactionRisk.Protocol.Lastupdated">
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier">
        <valueIdentifier>
          <system
                  value="https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2"/>
          <value value="at0062"/>
        </valueIdentifier>
      </extension>
      <path value="AdverseReactionRisk.Protocol.Lastupdated"/>
      <short value="Last updated"/>
      <definition
                  value="Date when the propensity or the reaction event was updated."/>
      <min value="0"/>
      <max value="1"/>
      <type>
        <code value="dateTime"/>
      </type>
      <mustSupport value="true"/>
    </element>
    <element id="AdverseReactionRisk.Protocol.Extension">
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier">
        <valueIdentifier>
          <system
                  value="https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2"/>
          <value value="at0128"/>
        </valueIdentifier>
      </extension>
      <extension
                 url="https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations">
        <valueString
                     value="For example: local information requirements or additional metadata to align with FHIR equivalents."/>
      </extension>
      <path value="AdverseReactionRisk.Protocol.Extension"/>
      <short value="Extension"/>
      <definition
                  value="Additional information required to capture local content or to align with other reference models/formalisms."/>
      <comment
               value="**Considerations**

For example: local information requirements or additional metadata to align with FHIR equivalents."/>
      <min value="0"/>
      <max value="1"/>
      <type>
        <code value="Reference"/>
      </type>
      <mustSupport value="true"/>
    </element>
    <element id="AdverseReactionRisk.Data">
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier">
        <valueIdentifier>
          <system
                  value="https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2"/>
          <value value="data"/>
        </valueIdentifier>
      </extension>
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint">
        <valueString value="orientation:right"/>
      </extension>
      <path value="AdverseReactionRisk.Data"/>
      <short value="Data"/>
      <definition value="@ internal @"/>
      <min value="0"/>
      <max value="1"/>
      <type>
        <code value="BackboneElement"/>
      </type>
      <mustSupport value="true"/>
    </element>
    <element id="AdverseReactionRisk.Data.Substance">
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier">
        <valueIdentifier>
          <system
                  value="https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2"/>
          <value value="at0002"/>
        </valueIdentifier>
      </extension>
      <extension
                 url="https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations">
        <valueString
                     value="Both an individual substance and a substance class are valid entries in 'Substance'. A substance may be a compound of simpler substances, for example a medicinal product. It is strongly recommended that the 'Substance' is coded with a terminology capable of triggering decision support, where possible. For example: Snomed CT, DM+D, RxNorm, NDFRT, ATC, New Zealand Universal List of Medicines and Australian Medicines Terminology. Free text entry should only be used if there is no appropriate terminology available."/>
      </extension>
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint">
        <valueString value="orientation:right"/>
      </extension>
      <path value="AdverseReactionRisk.Data.Substance"/>
      <short value="Substance"/>
      <definition
                  value="Identification of a substance, or substance class, that is considered to put the individual at risk of an adverse reaction event."/>
      <comment
               value="**Considerations**

Both an individual substance and a substance class are valid entries in 'Substance'. A substance may be a compound of simpler substances, for example a medicinal product. It is strongly recommended that the 'Substance' is coded with a terminology capable of triggering decision support, where possible. For example: Snomed CT, DM+D, RxNorm, NDFRT, ATC, New Zealand Universal List of Medicines and Australian Medicines Terminology. Free text entry should only be used if there is no appropriate terminology available."/>
      <min value="1"/>
      <max value="1"/>
      <type>
        <code value="CodeableConcept"/>
      </type>
      <mustSupport value="true"/>
    </element>
    <element id="AdverseReactionRisk.Data.Activeinactivestatus">
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier">
        <valueIdentifier>
          <system
                  value="https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2"/>
          <value value="at0130"/>
        </valueIdentifier>
      </extension>
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint">
        <valueString value="orientation:right"/>
      </extension>
      <path value="AdverseReactionRisk.Data.Activeinactivestatus"/>
      <short value="Activeinactivestatus"/>
      <definition
                  value="Status about whether the adverse reaction risk statement is active or inactive."/>
      <min value="0"/>
      <max value="1"/>
      <type>
        <code value="Coding"/>
      </type>
      <mustSupport value="true"/>
    </element>
    <element id="AdverseReactionRisk.Data.Verificationstatus">
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier">
        <valueIdentifier>
          <system
                  value="https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2"/>
          <value value="at0063"/>
        </valueIdentifier>
      </extension>
      <extension
                 url="https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations">
        <valueString
                     value="Decision support would typically raise alerts for 'Unconfirmed' and 'Confirmed', and ignore a 'Refuted' reaction. Clinical systems may choose not to display Adverse reaction entries with a 'Refuted' status in the Adverse Reaction List. However, 'Refuted' may be useful for reconciliation of the adverse reaction list or when communicating between systems. Some implementations may choose to make this field mandatory. The free text data type will allow for local variation by enabling other value sets to be applied to this data element in a template - in this situation it is recommended that values should be coded using a terminology."/>
      </extension>
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint">
        <valueString value="orientation:right"/>
      </extension>
      <path value="AdverseReactionRisk.Data.Verificationstatus"/>
      <short value="Verification status"/>
      <definition
                  value="Assertion about the certainty of the propensity, or potential future risk, of the identified 'Substance' to cause a reaction."/>
      <comment
               value="**Considerations**

Decision support would typically raise alerts for 'Unconfirmed' and 'Confirmed', and ignore a 'Refuted' reaction. Clinical systems may choose not to display Adverse reaction entries with a 'Refuted' status in the Adverse Reaction List. However, 'Refuted' may be useful for reconciliation of the adverse reaction list or when communicating between systems. Some implementations may choose to make this field mandatory. The free text data type will allow for local variation by enabling other value sets to be applied to this data element in a template - in this situation it is recommended that values should be coded using a terminology."/>
      <min value="0"/>
      <max value="1"/>
      <type>
        <code value="Coding"/>
      </type>
      <mustSupport value="true"/>
    </element>
    <element id="AdverseReactionRisk.Data.Criticality">
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier">
        <valueIdentifier>
          <system
                  value="https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2"/>
          <value value="at0101"/>
        </valueIdentifier>
      </extension>
      <extension
                 url="https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations">
        <valueString
                     value="This can be regarded as a predictive judgement of a 'worst case scenario'. In most contexts 'Low' would be regarded as the default value."/>
      </extension>
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint">
        <valueString value="orientation:right"/>
      </extension>
      <path value="AdverseReactionRisk.Data.Criticality"/>
      <short value="Criticality"/>
      <definition
                  value="An indication of the potential for critical system organ damage or life threatening consequence."/>
      <comment
               value="**Considerations**

This can be regarded as a predictive judgement of a 'worst case scenario'. In most contexts 'Low' would be regarded as the default value."/>
      <min value="0"/>
      <max value="1"/>
      <type>
        <code value="CodeableConcept"/>
      </type>
      <mustSupport value="true"/>
    </element>
    <element id="AdverseReactionRisk.Data.Category">
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier">
        <valueIdentifier>
          <system
                  value="https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2"/>
          <value value="at0120"/>
        </valueIdentifier>
      </extension>
      <extension
                 url="https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations">
        <valueString
                     value="This data element has been included because it is currently being captured in some clinical systems. This data can be derived from the Substance where coding systems are used, and is effectively redundant in that situation."/>
      </extension>
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint">
        <valueString value="orientation:right"/>
      </extension>
      <path value="AdverseReactionRisk.Data.Category"/>
      <short value="Category"/>
      <definition value="Category of the identified 'Substance'."/>
      <comment
               value="**Considerations**

This data element has been included because it is currently being captured in some clinical systems. This data can be derived from the Substance where coding systems are used, and is effectively redundant in that situation."/>
      <min value="0"/>
      <max value="1"/>
      <type>
        <code value="CodeableConcept"/>
      </type>
      <mustSupport value="true"/>
    </element>
    <element id="AdverseReactionRisk.Data.Onsetoflastreaction">
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier">
        <valueIdentifier>
          <system
                  value="https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2"/>
          <value value="at0117"/>
        </valueIdentifier>
      </extension>
      <extension
                 url="https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations">
        <valueString
                     value="For example: the actual date and/or time of onset; the interval of time during which the onset occurred; the age of the individual at the time of the onset; or the duration of time since the onset occurred. A partial date is valid, using the DV_DATE_TIME data type, to record only a year."/>
      </extension>
      <path value="AdverseReactionRisk.Data.Onsetoflastreaction"/>
      <short value="Onset of last reaction"/>
      <definition
                  value="The date and/or time of the onset of the last known occurrence of a reaction event."/>
      <comment
               value="**Considerations**

For example: the actual date and/or time of onset; the interval of time during which the onset occurred; the age of the individual at the time of the onset; or the duration of time since the onset occurred. A partial date is valid, using the DV_DATE_TIME data type, to record only a year."/>
      <min value="0"/>
      <max value="1"/>
      <type>
        <code value="dateTime"/>
      </type>
      <type>
        <code value="string"/>
      </type>
      <mustSupport value="true"/>
    </element>
    <element id="AdverseReactionRisk.Data.Onsetoffirstreaction">
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier">
        <valueIdentifier>
          <system
                  value="https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2"/>
          <value value="at0133"/>
        </valueIdentifier>
      </extension>
      <extension
                 url="https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations">
        <valueString
                     value="For example: the actual date and/or time of onset; the interval of time during which the onset occurred; the age of the individual at the time of the onset; or the duration of time since the onset occurred. A partial date is valid, using the DV_DATE_TIME data type, to record only a year."/>
      </extension>
      <path value="AdverseReactionRisk.Data.Onsetoffirstreaction"/>
      <short value="Onset of first reaction"/>
      <definition
                  value="The onset of the first known occurrence of a reaction event."/>
      <comment
               value="**Considerations**

For example: the actual date and/or time of onset; the interval of time during which the onset occurred; the age of the individual at the time of the onset; or the duration of time since the onset occurred. A partial date is valid, using the DV_DATE_TIME data type, to record only a year."/>
      <min value="0"/>
      <max value="1"/>
      <type>
        <code value="dateTime"/>
      </type>
      <type>
        <code value="string"/>
      </type>
      <mustSupport value="true"/>
    </element>
    <element id="AdverseReactionRisk.Data.Reactionmechanism">
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier">
        <valueIdentifier>
          <system
                  value="https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2"/>
          <value value="at0058"/>
        </valueIdentifier>
      </extension>
      <extension
                 url="https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations">
        <valueString
                     value="Immune-mediated responses have been traditionally regarded as an indicator for escalation of significant future risk. Contemporary knowledge suggests that some reactions previously thought to be immune are actually non-immune and still carry life threatening risk. 

Immunological testing may provide supporting evidence for the mechanism and causative substance , but no tests are 100% sensitive or specific for a sensitivity. 

It is acknowledged that most clinicians will NOT be able to distinguish the mechanism of any specific reaction. However this data element is included because many legacy systems have captured this attribute."/>
      </extension>
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint">
        <valueString value="orientation:right"/>
      </extension>
      <path value="AdverseReactionRisk.Data.Reactionmechanism"/>
      <short value="Reaction mechanism"/>
      <definition
                  value="Identification of the underlying physiological mechanism for the adverse reaction."/>
      <comment
               value="**Considerations**

Immune-mediated responses have been traditionally regarded as an indicator for escalation of significant future risk. Contemporary knowledge suggests that some reactions previously thought to be immune are actually non-immune and still carry life threatening risk. 

Immunological testing may provide supporting evidence for the mechanism and causative substance , but no tests are 100% sensitive or specific for a sensitivity. 

It is acknowledged that most clinicians will NOT be able to distinguish the mechanism of any specific reaction. However this data element is included because many legacy systems have captured this attribute."/>
      <min value="0"/>
      <max value="1"/>
      <type>
        <code value="CodeableConcept"/>
      </type>
      <mustSupport value="true"/>
    </element>
    <element id="AdverseReactionRisk.Data.Reactioneventsummary">
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier">
        <valueIdentifier>
          <system
                  value="https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2"/>
          <value value="at0129"/>
        </valueIdentifier>
      </extension>
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint">
        <valueString value="orientation:right"/>
      </extension>
      <path value="AdverseReactionRisk.Data.Reactioneventsummary"/>
      <short value="Reaction event summary"/>
      <definition
                  value="Summary details about each adverse reaction event linked to exposure to the identified 'Substance'."/>
      <min value="0"/>
      <max value="*"/>
      <type>
        <code value="Reference"/>
        <targetProfile
                       value="https://aehrc.csiro.au/fhir/logical-models/AdverseReactionEvent"/>
      </type>
      <mustSupport value="true"/>
    </element>
    <element id="AdverseReactionRisk.Data.Comment">
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier">
        <valueIdentifier>
          <system
                  value="https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2"/>
          <value value="at0006"/>
        </valueIdentifier>
      </extension>
      <extension
                 url="https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations">
        <valueString
                     value="For example: including reason for flagging a 'Criticality' of 'High risk'; and instructions related to future exposure or administration of the Substance, such as administration within an Intensive Care Unit or under corticosteroid cover."/>
      </extension>
      <path value="AdverseReactionRisk.Data.Comment"/>
      <short value="Comment"/>
      <definition
                  value="Additional narrative about the propensity for the adverse reaction, not captured in other fields."/>
      <comment
               value="**Considerations**

For example: including reason for flagging a 'Criticality' of 'High risk'; and instructions related to future exposure or administration of the Substance, such as administration within an Intensive Care Unit or under corticosteroid cover."/>
      <min value="0"/>
      <max value="1"/>
      <type>
        <code value="string"/>
      </type>
      <mustSupport value="true"/>
    </element>
  </differential>
</StructureDefinition>